Alcon has unveiled data from the Vivity Registry Study of the AcrySof IQ Vivity and the AcrySof IQ Vivity Toric presbyopia-correcting intraocular lens (PCIOL).
The non-interventional registry, open-label, ambispective, multicentre, non-comparative study was conducted across 41 sites in Australia, Germany, Belgium, New Zealand, Portugal, the Netherlands, Spain and the UK.
It monitored the 12-month real-world post-cataract surgery experiences of more than 900 patients who were implanted with either of these lenses.
Three-quarters of patients reported no difficulty with their sight for activities in everyday life and 92% of them were satisfied with their sight.
No halos, glares or starbursts (common visual disturbances from splitting the light in a diffractive IOL) were observed in more than 91% of patients.
Patients also reported that they no longer needed glasses to see at arm’s length and far away.
In addition, binocular distance and intermediate uncorrected visual acuity were observed with mean Snellen visual acuity values of 20/20 and 20/25, respectively.
Alcon Europe surgical franchise vice-president Sunil Vasanth said: “Vivity is a first-of-its-kind, non-diffractive extended depth of focus IOL built with our proprietary X-WAVE technology, which stretches and shifts light without splitting it.
“Our real-world registry data gives surgeons the confidence that Vivity’s performance is sustained over time. This data is also important as it includes patients with common mild comorbidities like glaucoma, dry eye and retinopathy/maculopathy.”
